Genomma Lab Internacional Stock (OTC: GNMLF)

Latest news for Genomma Lab Internacional (OTC:GNMLF) Stock

Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

News

Intraday Update

Markets

Movers

Trading Ideas

ACGL

ACKRF

ADPT

AFTPF

ASMIY

AUTLF

BCEKF

BDRFY

BF-A

BF-B

BSDGF

CABO

CHOLF

CHTR

CLHI

CLHRF

COUP

DBOEY

DCGD

ELRFF

EPGG

EPRT

ESGRP

EVRG

GATGF

GNMLF

GPTX

GTBDF

HCHDF

HCHMY

HEBT

HELE

HLTEF

HMLA

IBDRY

IMKTA

IMOS

INFO

INVH

JBSS

KLAC

KNSL

LAHO

LOOP

MDLZ

MLYCF

MSMGF

NMGNF

NSRGF

Nestle Sponsored representing Registered Shares Series B

NSRGY

NTDOY

Nuveen Insured Dividend Advantage Municipal Fund

NXRT

NXTC

Stocks That Hit 52-Week Highs On Wednesday

GENOMMA LAB INTL SAB ORD by Genomma Lab International SAB DE CV

Genomma Lab Internacional SAB de CV

Genomma Lab Internacional

<p>Agreement Combines Procaps Oral Delivery System Technology and Manufacturing with Genomma&#39;s Strategic Marketing and Distribution Footprint</p>

PROC

Procaps And Genomma Lab Enter A Strategic Agreement To Manufacture And Market Softgel Products In Latin America

Management

GenMark Diagnostics Announces That Scott Mendel Was Appointed CEO

Comments

Genomma Lab Internacional

News

Latest news for Genomma Lab Internacional (OTC:GNMLF) Stock

Thursday, November 30, 2023

Monday, May 04, 2020

Wednesday, September 04, 2019

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga